鶹ý

DSM's Undisclosed Industry Ties; Antipsychotic Heart Risks; FOMO and Phone Addiction

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

A study in The BMJ revealed that 60% of U.S. panel members and task force members on had undisclosed industry funding, to the tune of $14.2 million. "Our study was not designed (nor could it be) to determine if these financial ties affected decision making," the authors wrote.

While apparent renewed interest in the development of novel antipsychotics may be a reason to be optimistic, that alone is not enough to improve outcomes for people with schizophrenia, cautioned an editorial in The Lancet discussing the in the pipeline.

More and more states are looking to protect kids from the . (Politico)

The antipsychotic drugs quetiapine and haloperidol were linked with an and sudden cardiac death stemming from drug-induced QT prolongation. (HeartRhythm)

Depression symptom increases were tied with a among people with overweight or obesity. (PLOS One)

The FDA approved BrainSee, a software platform that combines MRI and cognitive assessments to predict likelihood of , maker Darmiyan announced.

FOMO -- aka, the fear of missing out -- and boredom proneness played an important role in the relationship between symptoms of obsessive compulsive disorder and . (Current Psychology)

After a systematic evaluation, the only achieved a diagnostic classification accuracy of 62% for identifying the neural signature of major depressive disorder. (JAMA Psychiatry)

Anavex Life Sciences announced of its dual SIGMAR1 receptor agonist and M1 positive allosteric modulator ANAVEX3-71 for schizophrenia.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.